Elderly Vaccination

Elderly vaccination addresses how immunization is approached in older adults, whose age-related decline in immune function -- immunosenescence -- both weakens vaccine responses and raises the risk of severe vaccine-preventable disease. This combination has driven the development of higher-immunogenicity formulations, including high-dose and adjuvanted vaccines, designed to improve protection in this group.

Definition

Elderly vaccination refers to immunization in older adults, in whom age-related immune decline (immunosenescence) reduces vaccine responses and increases susceptibility to severe vaccine-preventable disease, motivating the use of higher-dose or adjuvanted formulations to improve protection.

Scope

The topic covers immunosenescence and its effect on vaccine response, the elevated burden of influenza, pneumococcal disease, and herpes zoster in older adults, and the rationale for enhanced formulations (high-dose influenza, adjuvanted and recombinant vaccines) developed to overcome reduced immunogenicity. It is a reference account of the principles and supporting trial evidence, not individualized vaccination advice.

Core questions

• How does immunosenescence change the response to vaccination in older adults?
• Why do older adults bear a higher burden of severe vaccine-preventable disease?
• What is the rationale for high-dose and adjuvanted vaccine formulations?
• What does randomized evidence show about enhanced influenza and zoster vaccines in older adults?

Key concepts

• Immunosenescence
• Inflammaging
• Reduced vaccine immunogenicity with age
• High-dose influenza vaccine
• Adjuvanted and recombinant vaccine formulations
• Herpes zoster reactivation risk with age
• Pneumococcal disease burden in older adults

Mechanisms

Ageing remodels the immune system: the output of naive T cells declines, the T-cell repertoire narrows, and B-cell and germinal-centre function weakens, so antigen exposure -- including vaccination -- produces lower and shorter-lived antibody responses (goronzy-2019). A parallel low-grade chronic inflammatory state ('inflammaging') further alters responsiveness. Declining cell-mediated immunity also permits reactivation of latent varicella-zoster virus, raising herpes zoster risk. To compensate for blunted responses, vaccines for older adults use higher antigen content or adjuvants: a high-dose inactivated influenza vaccine improved efficacy over standard dose in a randomized trial, and an adjuvanted recombinant zoster subunit vaccine and pneumococcal conjugate vaccine demonstrated efficacy in older-adult trials (diazgranados-2014; lal-2015; bonten-2015).

Clinical relevance

Older adults are a priority group for several routine vaccines because of their elevated risk of severe outcomes, and the principles here explain why enhanced formulations exist for them. The entry is reference material describing those principles and the trial evidence; it does not give individualized vaccination recommendations.

Epidemiology

Influenza, invasive pneumococcal disease, and herpes zoster all rise sharply in incidence and severity with age, concentrating much of their morbidity and mortality in older adults. This burden, together with reduced vaccine responsiveness, is the rationale for age-targeted immunization programmes and enhanced formulations (diazgranados-2014; bonten-2015).

Evidence & guidelines

Randomized trials underpin the enhanced-formulation strategy: a high-dose inactivated influenza vaccine showed superior efficacy to standard dose in adults aged 65 and older (diazgranados-2014); an adjuvanted recombinant zoster subunit vaccine showed high efficacy against herpes zoster in older adults (lal-2015); and a pneumococcal conjugate vaccine demonstrated efficacy against vaccine-type pneumococcal pneumonia in older adults (bonten-2015). The immunological basis is reviewed in the ageing-immunity literature (goronzy-2019), and standard vaccinology references synthesise older-adult immunization (plotkin-2018).

History

Recognition that older adults respond less well to vaccines led, over the late twentieth and early twenty-first centuries, to a deliberate effort to design better-performing formulations for them. The high-dose influenza vaccine trial, the adjuvanted recombinant zoster vaccine trial, and the pneumococcal conjugate vaccine trial in older adults each marked steps in tailoring immunization to the ageing immune system (diazgranados-2014; lal-2015; bonten-2015).

Debates

How best to overcome immunosenescence for vaccine protection?

Different strategies -- higher antigen dose, adjuvantation, and recombinant platforms -- have each shown benefit in older adults, and how to combine or prioritise them across pathogens remains an active area of vaccine development.

Key figures

• Jorg Goronzy
• Carlos DiazGranados
• Anthony Cunningham

Seminal works

• diazgranados-2014
• lal-2015
• bonten-2015

Frequently asked questions

Why do older adults sometimes receive high-dose or adjuvanted vaccines?

Age-related immune decline reduces the response to standard vaccines, so higher-dose or adjuvanted formulations are designed to generate stronger protection; randomized trials have shown improved efficacy for high-dose influenza and adjuvanted zoster vaccines in older adults.

What is immunosenescence?

Immunosenescence is the age-related decline in immune function -- including reduced production of naive T cells and weaker antibody responses -- that lowers vaccine effectiveness and increases susceptibility to severe infection in older adults.